We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

98 hedge funds and large institutions have $160M invested in Yarrow Bioscience, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 53 increasing their positions, 7 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

657% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 7

73% more capital invested

Capital invested by funds: $92.7M → $160M (+$67.5M)

57% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 21

14% more funds holding

Funds holding: 8698 (+12)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% less ownership

Funds ownership: 0.02%0.01% (-0%)

Holders
98
Holders Change
+12
Holders Change %
+13.95%
% of All Funds
2.01%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
33
Increased
53
Reduced
7
Closed
21
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$39.6M +$30.5M +4,511 +245%
N
2
Nuveen
North Carolina
$15.6M +$582K +86 +232%
BlackRock
3
BlackRock
New York
$14.2M +$9.88M +1,459 +177%
Vanguard Group
4
Vanguard Group
Pennsylvania
$12.1M +$11.3M +1,662 +587%
Franklin Resources
5
Franklin Resources
California
$11.7M +$12.7M +1,877 New
6CM
6
683 Capital Management
New York
$9.6M +$6.68M +987 +178%
DA
7
DSC Advisors
Illinois
$7.54M +$4.29M +634 +110%
Axa
8
Axa
France
$6.38M +$5.48M +810 +377%
VC
9
Vivo Capital
California
$6.3M -$379K -56 -5%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.13M +$2.52M +372 +284%
HVC
11
Healthcare Value Capital
New Jersey
$2.94M +$1.6M +236 +100%
State Street
12
State Street
Massachusetts
$2.53M +$1.46M +216 +114%
Millennium Management
13
Millennium Management
New York
$2.38M +$2.58M +381 New
Northern Trust
14
Northern Trust
Illinois
$2.25M +$1.59M +235 +185%
CCM
15
CAAS Capital Management
New York
$2.05M +$2.23M +329 New
MIM
16
Monashee Investment Management
Massachusetts
$1.74M +$1.89M +279 New
Morgan Stanley
17
Morgan Stanley
New York
$1.54M -$129K -19 -7%
SI
18
Sofinnova Investments
California
$1.26M +$230K +34 +20%
BBVA
19
Banco Bilbao Vizcaya Argentaria
Spain
$1.12M +$1.13M +167 +1,285%
O
20
OrbiMed
New York
$1.03M -$2.17M -321 -66%
Bank of America
21
Bank of America
North Carolina
$986K +$853K +126 +394%
TCM
22
Tekla Capital Management
Massachusetts
$937K +$684K +101 +206%
Citadel Advisors
23
Citadel Advisors
Florida
$875K +$921K +136 +3,400%
Two Sigma Investments
24
Two Sigma Investments
New York
$873K +$948K +140 New
Baillie Gifford & Co
25
Baillie Gifford & Co
United Kingdom
$683K +$501K +74 +206%

YARW Hedge Fund Activity: Q2 2020 in Review

98 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q2 2020, worth a combined $160M — up 73% from $92.7M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new YARW positions and 21 closed out — a net gain of 12 holders — while 53 added to existing stakes and 7 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $30.5M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.43M sold.

  • 98 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q2 2020, up from 86 in Q1 2020.
  • Funds reported $160M of Yarrow Bioscience, Inc. Common Stock stock for Q2 2020, up 73% quarter-over-quarter.
  • 33 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q2 2020 and 21 closed out, a net change of +12 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q2 2020 was Perceptive Advisors, an estimated $30.5M added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q2 2020 was Great Point Partners, an estimated $4.43M sold.

Based on aggregated 13F filings for Q2 2020.